Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Development of CM-IAV1 for Treatment of High-risk Pandemic Influenzas

Award Number: R44AI157074
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 04/25/2022
PERIOD OF PERFORMANCE END DATE: 05/30/2026

Group Awards By:

View Award Description

Development of CM-IAV1 for Treatment of High-risk Pandemic Influenzas - Health and Human Services (HHS) and the Biomedical Advanced Research and Development Authority (BARDA) have identified a severe pandemic influenza outbreak as one of the greatest threats to national and global security. The Centers for Disease Control (CDC) warn that viruses like H7N9 and H5N1, with fatality rates of approximately 40% and 60% respectively, could lead to catastrophic outcomes if they were to trigger a pandemic, with models predicting infection in one-third of the world’s population. This project focuses on advancing the development of CM-PW3, a broadly neutralizing, cross-reactive human monoclonal antibody for prophylactic use in high-risk populations, providing targeted, preemptive protection against both seasonal and pandemic influenza strains, including H1N1, H5N1, and H7N9. We will evaluate the most efficient and economic delivery of the antibody and determine the expected duration of protection. The overarching goal of this program is to develop CMPW3 to provide passive, immediate pre-exposure protection to at-risk individuals for an entire influenza season (or >4 months).


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $0 )
2025	2024	CELDARA MEDICAL, LLC	16 CAVENDISH CT STE 240	LEBANON	NH	03766	GRAFTON	USA	Allergy and Infectious Diseases Research	000	3	11/18/2024	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2024 ( Subtotal = $998,375 )
2024	2024	CELDARA MEDICAL	16 CAVENDISH CT	LEBANON	NH	03766	GRAFTON	USA	Allergy and Infectious Diseases Research	000	3	5/16/2024	NON-COMPETING CONTINUATION	$998,375
2024	2022	CELDARA MEDICAL, LLC	16 CAVENDISH CT STE 240	LEBANON	NH	03766	GRAFTON	USA	Allergy and Infectious Diseases Research	001	1	7/25/2024	NEW	$0
														Subtotal = $998,375

Issue Date FY: 2023 ( Subtotal = $999,635 )
2023	2023	CELDARA MEDICAL, LLC	16 CAVENDISH CT	LEBANON	NH	03766	GRAFTON	USA	Allergy and Infectious Diseases Research	000	2	6/12/2023	EXTENSION WITH OR WITHOUT FUNDS	$999,635
														Subtotal = $999,635

Issue Date FY: 2022 ( Subtotal = $300,000 )
2022	2022	CELDARA MEDICAL, LLC	16 CAVENDISH CT	LEBANON	NH	03766	GRAFTON	USA	Allergy and Infectious Diseases Research	000	1	4/25/2022	NEW	$300,000
														Subtotal = $300,000

Grand Total All Awards = $2,298,010

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Development of CM-IAV1 for Treatment of High-risk Pandemic Influenzas

Award Number: R44AI157074

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 04/25/2022

PERIOD OF PERFORMANCE END DATE: 05/30/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer